Skip to main content
logo
Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
25.86
+0.94 (3.77%)
Aug 19, 2026, 4:00 PM EDT - Market closed

Bicara Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22
Market Capitalization
1,711922948--
Market Cap Growth
169.44%-2.74%---
Enterprise Value
1,215634428--
Last Close Price
25.8616.8317.42--

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22
PB Ratio
3.642.301.93--
P/TBV Ratio
3.652.301.93--

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22
Debt / Equity Ratio
0.000.000.000.00-
Net Debt / Equity Ratio
-1.06-1.03-0.99-1.050.24
Net Debt / EBITDA Ratio
2.462.665.945.760.11
Net Debt / FCF Ratio
3.673.866.544.970.13
Quick Ratio
11.4414.3327.2215.280.17
Current Ratio
11.5914.5827.9315.320.21
Return on Equity (ROE)
-41.01%-30.88%-19.14%-51.67%-
Return on Assets (ROA)
-26.14%-20.67%-13.84%-20.72%-
Return on Capital Employed (ROCE)
-43.10%-38.70%-16.70%-18.20%219.00%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22
Earnings Yield
-10.83%-14.96%-7.17%--
FCF Yield
-7.90%-11.62%-7.89%--
Buyback Yield / Dilution
-36.51%-225.35%-2796.96%-35.20%-
SEC Filings: 10-K · 10-Q